Cargando…
MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis
Conventional chemotherapy for killing cancer cells using cytotoxic drugs suffers from low selectivity, significant toxicity, and a narrow therapeutic index. Hyper-specific targeted drugs achieve precise destruction of tumors by inhibiting molecular pathways that are critical to tumor growth. Myeloid...
Autores principales: | Zhang, Hexiao, Li, Fei, Yang, Ming, Zhang, Wenshan, He, Mei, Xu, Hui, Wang, Chaoqun, Zhang, Yiran, Wang, Wei, Gao, Yingdai, Du, Xue, Li, Yinghui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144179/ https://www.ncbi.nlm.nih.gov/pubmed/37111571 http://dx.doi.org/10.3390/pharmaceutics15041085 |
Ejemplares similares
-
Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
por: Liu, Dongyan, et al.
Publicado: (2021) -
Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
por: Liu, Dongyan, et al.
Publicado: (2021) -
Levistilide A Promotes Expansion of Human Umbilical Cord Blood Hematopoietic Stem Cells by Enhancing Antioxidant Activity
por: He, Mei, et al.
Publicado: (2022) -
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
por: Mukherjee, Nabanita, et al.
Publicado: (2020) -
Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
por: Malyukova, Alena, et al.
Publicado: (2021)